Cell Biology of NMB in Pigmentary Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
July 01, 2012 - August 31, 2014
Grant ID
G2012025
Goals
DBA/2J mice are an animal model of pigment dispersion syndrome (PDS), which is a precursor to glaucoma in humans. These mice are thought to have a loss-of-function mutation in the NMB gene that is responsible for this disease. Dr. Theos and colleagues are proposing experiments that will characterize the NMB protein within pigmented cells of the eye in order to understand how NMB functions in normal cells, and, in addition, how loss of function of NMB causes PDS.
Summary
Dr. Theos and colleagues will look at the cells in the eye that produce the pigment that gives the iris its color. These cells die as a prelude to the development of a type of inherited glaucoma known as pigmentary glaucoma (PG). Unfortunately, very little is known about why these particular cells within the eye do not survive with age and cause problems that lead to the disease. These researchers will use cells from the eyes of DBA/2J mice that develop PDS to test if a specific protein, called NMB, is important for keeping the cells healthy by making and storing these pigments within the confines of a specialized cell compartment. To get a handle on this, the researchers will first determine if the normal protein is in the right place within cells to carry out this type of function.
The results of this research may have an impact on other devastating diseases, as NMB has recently been shown to be critically important not only in PG, but also in a rare but devastating cancer of the eye called uveal melanoma. If Theos and colleagues can fully understand how NMB leads to changes in the behavior of eye cells, this will help to develop new therapies to correct the problem or even prevent the development of these debilitating diseases.
Related Grants
National Glaucoma Research
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
Exploring Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Qi Cui, MD, PhD
Current Organization
University of Pennsylvania, Perelman School of Medicine
National Glaucoma Research
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
Measuring the Effects of Visual Stimuli on Retinal Blood Vessels and Flow
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Stuart Gardiner, PhD
Current Organization
Good Samaritan Foundation, Legacy Health System
National Glaucoma Research
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine
Reducing Inflammation to Protect Vision in Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Cátia Gomes, PhD
Current Organization
Indiana University School of Medicine